Summary
32 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $180.0M against $40.2M.
- It beat profit estimates 8 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Revenue grew by only 2.5% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.7% a year over 5 years. Over the last 3 years it grew by 2.5% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $109.9M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.1 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $57.6 is 40% above today's price. 64% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 47%
- Qelbree 23%
- GOCOVRI 11%
- Collaboration Revenue 4.0%
- APOKYN 3.6%
- Other 11%
By region
The company reports no revenue by region.
Product brings in 47% of revenue. Qelbree grew fastest, by 136% a year.
Segments in detail